by Jang Hyowon
Published 11 Aug.2021 10:25(KST)
[Asia Economy Reporter Jang Hyowon] VGXI, a subsidiary of Jinwon Life Sciences, is showing strong performance following news of its participation as a partner in the development of gene therapies for rare diseases.
As of 10:25 AM on the 11th, Jinwon Life Sciences is trading at 43,500 KRW, up 3.69% from the previous day.
On this day, Jinwon Life Sciences announced that its DNA vaccine and gene therapy specialized contract development and manufacturing organization (CDMO) subsidiary VGXI will participate as a partner in a rare disease gene therapy development project supported by the non-profit organization 'Rare Trait Hope Fund.'
VGXI plans to produce and supply plasmid raw materials for clinical-grade pharmaceuticals for the gene therapy of the rare disease aspartylglucosaminuria (AGU).
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.